miR-125b and miR-532-3p predict the efficiency of rituximab-mediated lymphodepletion in chronic lymphocytic leukemia patients. A French Innovative Leukemia Organization study.

MLA

Gagez, Anne-Laure, et al. “MiR-125b and MiR-532-3p Predict the Efficiency of Rituximab-Mediated Lymphodepletion in Chronic Lymphocytic Leukemia Patients. A French Innovative Leukemia Organization Study.” Haematologica, vol. 102, no. 4, Apr. 2017, pp. 746–54. EBSCOhost, https://doi.org/10.3324/haematol.2016.153189.

APA

Gagez, A.-L., Duroux-Richard, I., Leprêtre, S., Orsini-Piocelle, F., Letestu, R., De Guibert, S., Tuaillon, E., Leblond, V., Khalifa, O., Gouilleux-Gruart, V., Banos, A., Tournilhac, O., Dupuis, J., Jorgensen, C., Cartron, G., & Apparailly, F. (2017). miR-125b and miR-532-3p predict the efficiency of rituximab-mediated lymphodepletion in chronic lymphocytic leukemia patients. A French Innovative Leukemia Organization study. Haematologica, 102(4), 746–754. https://doi.org/10.3324/haematol.2016.153189

Chicago

Gagez, Anne-Laure, Isabelle Duroux-Richard, Stéphane Leprêtre, Frédérique Orsini-Piocelle, Rémi Letestu, Sophie De Guibert, Edouard Tuaillon, et al. 2017. “MiR-125b and MiR-532-3p Predict the Efficiency of Rituximab-Mediated Lymphodepletion in Chronic Lymphocytic Leukemia Patients. A French Innovative Leukemia Organization Study.” Haematologica 102 (4): 746–54. doi:10.3324/haematol.2016.153189.